The funding aims to investigate Molli’s effect on pain in stroke patients and thereby increase the knowledge of the processes that Mollii gives rise to. In this way, the company can further develop the suit to the purpose, pain. The clinical study will be conducted by the Karolinska Institutet and will be performed at Danderyd’s Hospital, Sweden.
“Being able to create a longer persistent pain relief, without the need of painkillers or other types of drugs, would be of great value both for the individual and for the health and medical care.”, says Mimi Westerlund, Chief Research Officer at Inerventions. The study will begin in August.
For further information please contact:
Mimi Westerlund, Chief Research Officer
Telephone: +46 8-410 277 01
Inerventions is a Stockholm-based company that helps people to a life in motion. The company has developed the product Mollii, which is used by people with neurological injuries and diseases such as CP, acquired brain injury, spinal cord injury, Stroke and MS.